Yao Hao

Dr. Yao Hao

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2024 in Journal of Applied Clinical Medical Physics
Verified
Journal Article
Open access
EKEuidam Kim
Euidam Kim
YPYang Kyun Park
Yang Kyun Park
TZTianyu Zhao
Tianyu Zhao
ELEric Laugeman
Eric Laugeman
XZXiaodong Neo Zhao
Xiaodong Neo Zhao
HLHugh Lee
Hugh Lee
Purpose: The quality of on‐board imaging systems, including cone‐beam computed tomography (CBCT), plays a vital role in image‐guided radiation therapy (IGRT) and adaptive radiotherapy. Recently, there has been an upgrade of the CBCT systems fused in the O‐ring linear accelerators called HyperSight, featuring a high imaging performance. As the characterization of a new imaging system is essential, we evaluated the image quality of the HyperSight system by comparing it with Halcyon 3.0 CBCT and providing benchmark data for routine imaging quality assurance.Methods: The HyperSight features ultra‐fast scan time, a larger kilovoltage (kV) detector, a more substantial kV tube, and an advanced reconstruction algorithm. Imaging protocols in the two modes of operation, treatment mode with IGRT and the CBCT for planning (CBCTp) mode were evaluated and compared with Halcyon 3.0 CBCT. Image quality metrics, including spatial resolution, contrast resolution, uniformity, noise, computed tomography (CT) number linearity, and calibration error, were assessed using a Catphan and an electron density phantom and analyzed with TotalQA software.Results: HyperSight demonstrated substantial improvements in contrast‐to‐noise ratio and noise in both IGRT and CBCTp modes compared to Halcyon 3.0 CBCT. CT number calibration error of HyperSight CBCTp mode (1.06%) closely matches that of a full CT scanner (0.72%), making it suitable for adaptive planning. In addition, the advanced hardware of HyperSight, such as ultra‐fast scan time (5.9 s) or 2.5 times larger heat unit capacity, enhanced the clinical efficiency in our experience.Conclusions: HyperSight represented a significant advancement in CBCT imaging. With its image quality, CT number accuracy, and ultra‐fast scans, HyperSight has a potential to transform patient care and treatment outcomes. The enhanced scan speed and image quality of HyperSight are expected to significantly improve the quality and efficiency of treatment, particularly benefiting patients.

14 November 2022 in IEEE Transactions on Biomedical Engineering
Verified
Journal Article
Closed access
LXLu Xu
Lu Xu
CPChristopher P. Pacia
Christopher P. Pacia
YGYan Gong
Yan Gong
ZHZhongtao Hu
Zhongtao Hu
CCChih-Yen Chien
Chih-Yen Chien
HCHong Chen
Hong Chen
Focused ultrasound (FUS)-enabled liquid biopsy (sonobiopsy) is an emerging technique for the noninvasive and spatiotemporally controlled diagnosis of brain cancer by inducing blood-brain barrier (BBB) disruption to release brain tumor-specific biomarkers into the blood circulation. The feasibility, safety, and efficacy of sonobiopsy were demonstrated in both small and large animal models using magnetic resonance-guided FUS devices. However, the high cost and complex operation of magnetic resonance-guided FUS devices limit the future broad application of sonobiopsy in the clinic. In this study, a neuronavigation-guided sonobiopsy device is developed and its targeting accuracy is characterized in vitro , in vivo , and in silico . The sonobiopsy device integrated a commercially available neuronavigation system (BrainSight) with a nimble, lightweight FUS transducer. Its targeting accuracy was characterized in vitro in a water tank using a hydrophone. The performance of the device in BBB disruption was verified in vivo using a pig model, and the targeting accuracy was quantified by measuring the offset between the target and the actual locations of BBB opening. The feasibility of the FUS device in targeting glioblastoma (GBM) tumors was evaluated in silico using numerical simulation by the k-Wave toolbox in glioblastoma patients. It was found that the targeting accuracy of the neuronavigation-guided sonobiopsy device was 1.7 ± 0.8 mm as measured in the water tank. The neuronavigation-guided FUS device successfully induced BBB disruption in pigs with a targeting accuracy of 3.3 ± 1.4 mm. The targeting accuracy of the FUS transducer at the GBM tumor was 5.5 ± 4.9 mm. Age, sex, and incident locations were found to be not correlated with the targeting accuracy in GBM patients. This study demonstrated that the developed neuronavigation-guided FUS device could target the brain with a high spatial targeting accuracy, paving the foundation for its application in the clinic.

1 April 2016 in Physica Medica
Verified
Journal Article
Closed access
ZOZi Ouyang
Zi Ouyang
MMMadan Kumar Mainali
Madan Kumar Mainali
NSNeeharika Sinha
Neeharika Sinha
GSGuinevere Strack
Guinevere Strack
YAYucel Altundal
Yucel Altundal
WNWilfred Ngwa
Wilfred Ngwa

24 October 2023 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
MWMichael Waters
Michael Waters
APAlex Price
Alex Price
ELEric Laugeman
Eric Laugeman
LHLauren Henke
Lauren Henke
GHGeoff Hugo
Geoff Hugo
BBBrian C. Baumann
Brian C. Baumann
Stereotactic body radiation therapy (SBRT) is an emerging treatment modality for clinically localized prostate cancer (PCa). Online daily adaptive radiotherapy (ART) could potentially improve the therapeutic ratio of prostate SBRT by accounting for inter-fraction variation in target and OAR volumes. To our knowledge, no group has evaluated the clinical utility of a novel AI-augmented CT-based ART system for prostate SBRT. In this study we hypothesized that adaptive prostate SBRT plans would result in improved target coverage and lower dose to OARs in comparison to unadapted treatment plans. Seven patients with favorable intermediate to oligometastatic PCa treated with 5-fx prostate adaptive SBRT were retrospectively reviewed. Patients were treated with 3625 cGy to the prostate and seminal vesicles. 6 patients additionally received 2500 cGy to the pelvic nodes, 5 patients underwent a boost to 4000 cGy to the prostate. For each fraction, a CBCT was acquired and OARs (rectum, bladder, bowel, sigmoid, femurs) were segmented/deformed using AI. CTVs were rigidly registered. Volumes were adjusted manually and PTV expansions added. Adaptive treatment plans were developed based on the contoured targets and OARs and dose to these volumes for the adapted vs. initial plans were compared for each fraction. V100 and the D0.03 cc between scheduled and adapted treatment plans were compared using a Student’s t-test, with significance threshold of P < 0.05. Seven patients completed 35 Fx’s of adaptive RT. Daily adaptation resulted in a statistically significant mean improvement in PTV V100 for all targets: [21.4 % ± 4.3 % for PTV 4000 (p < 0.0001); 8.7 % ± 1.1 % for PTV 3625 (p < 0.0001); and 11.5 % ± 3.1 % for PTV 2500 (p = 0.0013)]. Mean rectal D0.03 was significantly reduced by 38.8 cGy ± 5.95 cGy (p < 0.0001) per fraction (194 cGy/5 fractions) compared to the initial plans. There was a modest increase in bladder dose of 10.9 cGy ± 4.93 cGy per fraction (p = 0.0424) for the adaptive plans. The adaptive plans met bladder constraints for every fraction. There were no statistically significant differences between sigmoid or bowel dose for adapted vs. initial plans. No patients experienced acute CTCAE grade ≥ 3 GI/GU adverse events (median F/U 9.5 months). All statistically significant differences were maintained in the presence and absence of rectal hydrogel spacer (p < 0.05). CT-based online adaptive SBRT resulted in statistically significant and clinically meaningful improvements in PTV coverage and D0.03 cc dose to the rectum. A trial evaluating CT adaptive whole-pelvis prostate SBRT is underway.

20 December 2022 in Medical Dosimetry
Verified
Journal Article
Closed access
JGJohn S. Ginn
John S. Ginn
HGHiram A. Gay
Hiram A. Gay
JHJessica Hilliard
Jessica Hilliard
JSJainil Shah
Jainil Shah
NMNilesh Mistry
Nilesh Mistry
YHYao Hao
Yao Hao

1 January 2021 in Brachytherapy
Verified
Journal Article
Closed access
NMNichole M. Maughan
Nichole M. Maughan
HKHyun Kim
Hyun Kim
YHYao Hao
Yao Hao
SUSamantha Unangst
Samantha Unangst
MRMichael C. Roach
Michael C. Roach
JZJacqueline E. Zoberi
Jacqueline E. Zoberi